Research News
Reducing Hepatitis B Reactivation Risks in Cancer Patients
A systematic review and meta-analysis published in *Seminars in Oncology* reveals critical insights into hepatitis B virus (HBV) reactivation among cancer patients undergoing chemotherapy. The study highlights that while the overall HBV reactivation rate is 9%, the risk significantly decreases to 4% with the use of antiviral prophylaxis, such as tenofovir or entecavir, which are the most effective options.
Key Findings
- Patients with hematologic cancers have a higher HBV reactivation rate (10%) compared to those with solid tumors (5%).
- Antiviral prophylaxis is essential, reducing reactivation rates across all cancer types and chemotherapy regimens, including those containing rituximab.
Significance
This study emphasizes the importance of preemptive HBV screening and antiviral therapy to mitigate risks and improve cancer treatment outcomes.
Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hos-
pital, Thai Red Cross Society, 1873 Rama IV Road, Patumwan, Bangkok, 10330, Thai-
land.